Penumbra (PEN) EPS (Basic) Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.15% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.72% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -1.10% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 62.43% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 10.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 58.74% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 26.49% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 5.98% |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | 55.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.67% |
| Dec 31, 2025 | 129.58% |
| Sep 30, 2025 | 178.06% |
| Jun 30, 2025 | 139.28% |
| Mar 31, 2025 | 686.26% |
| Dec 31, 2024 | 49.15% |
| Sep 30, 2024 | 46.85% |
| Jun 30, 2024 | -101.65% |
| Mar 31, 2024 | -4.35% |
| Dec 31, 2023 | 141.01% |
| Sep 30, 2023 | 44.22% |
| Jun 30, 2023 | 50.97% |
| Mar 31, 2023 | 76.52% |
| Dec 31, 2022 | -29.05% |
| Sep 30, 2022 | -29.70% |
| Jun 30, 2022 | -30.22% |
| Mar 31, 2022 | -81.08% |
| Dec 31, 2021 | -76.24% |
| Sep 30, 2021 | 34.56% |
| Jun 30, 2021 | -13.78% |
| Mar 31, 2021 | 25.99% |
| Dec 31, 2020 | -28.19% |
| Sep 30, 2020 | -196.25% |
| Jun 30, 2020 | -89.45% |
| Mar 31, 2020 | 33.89% |
| Dec 31, 2019 | 76.52% |
| Sep 30, 2019 | -5.42% |
| Jun 30, 2019 | 68.69% |
| Mar 31, 2019 | 57.07% |
| Dec 31, 2018 | 56.05% |
| Sep 30, 2018 | -150.66% |
| Jun 30, 2018 | 77.00% |
| Mar 31, 2018 | 16.96% |
| Dec 31, 2017 | 138.11% |
| Sep 30, 2017 | 26.83% |
| Jun 30, 2017 | -65.10% |
| Mar 31, 2017 | -54.20% |